Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
Chiricozzi A., Balato A., Conrad C., Conti A., Dapavo P., Ferreira P., Gaiani F.M., Leite L., Malagoli P., Mendes-Bastos P. et al., 2020/08. The Journal of dermatological treatment, 31 (5) pp. 476-483. Peer-reviewed.
ici le détail